# Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/7cf691b8-82e3-41a4-a550-b4285ce9a9bf

> FDA guidance document: Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence. Issue date: October 24, 2023. Get complete insights and analysis.

---

## Details

- Title: Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-10-24
- Last Changed: 2023-10-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-2170">FDA-2022-D-2170</a>

## Related Documents

- [Sameness Evaluations in an ANDA — Active Ingredients](https://www.globalkeysolutions.net/guidances/guidance-document/sameness-evaluations-in-an-anda-active-ingredients/56e63be0-f1f7-48cf-90e1-c9eb340486ef)
- [In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs](https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-release-test-studies-for-topical-drug-products-submitted-in-andas/c7ff8356-0869-42f7-a5dc-76e32fe0380b)
- [In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs](https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-permeation-test-studies-for-topical-drug-products-submitted-in-andas/8770bfc5-6951-467a-905c-ebd361ba4aac)